IPO Databook: Starton Holdings (STA US) - Jul 2026

106 Views17 Jul 2026 10:15

SUMMARY

Starton Holdings, a clinical-stage biotechnology company, uses its proprietary continuous delivery platform to improve cancer therapies, funding STAR-LLD development via an IPO.
The company holds 8 issued patents and has STAR-LLD-SC in Phase 2a for RRMM. STAR-LLD-OCR entered human study in Q1/2026.
The company reported a $15.4 million net loss for 2026 and an $89.2 million accumulated deficit, raising substantial doubt about its "going concern" ability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream